Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma

O'Callaghan J, Delaney C, O'Connor M, van Batenburg-Sherwood J, Schicht M, Lütjen-Drecoll E, Hudson N, Ni Dhubhghaill S, Humphries P, Stanley C, Keravala A, Chalberg T, Lawrence MS, Campbell M (2023)

Publication Type: Journal article

Publication year: 2023


Book Volume: 9

Pages Range: eadf6537-

Journal Issue: 16

DOI: 10.1126/sciadv.adf6537


Approximately 80 million people globally are affected by glaucoma, with a projected increase to over 110 million by 2040. Substantial issues surrounding patient compliance remain with topical eye drops, and up to 10% of patients become treatment resistant, putting them at risk of permanent vision loss. The major risk factor for glaucoma is elevated intraocular pressure, which is regulated by the balance between the secretion of aqueous humor and the resistance to its flow across the conventional outflow pathway. Here, we show that adeno-associated virus 9 (AAV9)-mediated expression of matrix metalloproteinase-3 (MMP-3) can increase outflow in two murine models of glaucoma and in nonhuman primates. We show that long-term AAV9 transduction of the corneal endothelium in the nonhuman primate is safe and well tolerated. Last, MMP-3 increases outflow in donor human eyes. Collectively, our data suggest that glaucoma can be readily treated with gene therapy-based methods, paving the way for deployment in clinical trials.

Authors with CRIS profile

Involved external institutions

How to cite


O'Callaghan, J., Delaney, C., O'Connor, M., van Batenburg-Sherwood, J., Schicht, M., Lütjen-Drecoll, E.,... Campbell, M. (2023). Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma. Science Advances, 9(16), eadf6537-.


O'Callaghan, Jeffrey, et al. "Matrix metalloproteinase-3 (MMP-3)-mediated gene therapy for glaucoma." Science Advances 9.16 (2023): eadf6537-.

BibTeX: Download